Arcturus Therapeutics Approves Key Proposals at Annual Meeting

The latest announcement is out from Arcturus Therapeutics ( (ARCT) ).

On June 6, 2025, Arcturus Therapeutics held its annual stockholders meeting where key proposals were voted on, including the election of nine directors to the Board, approval of executive compensation, and the ratification of Deloitte as the independent accounting firm for 2025. All proposals were approved, indicating strong shareholder support for the company’s leadership and strategic direction.

The most recent analyst rating on (ARCT) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.

Spark’s Take on ARCT Stock

According to Spark, TipRanks’ AI Analyst, ARCT is a Neutral.

Arcturus Therapeutics’ overall score reflects a blend of financial challenges and technical resilience. Financial performance is constrained by consistent losses and declining revenue, but technical indicators show short-term bullish trends. The company’s strategic focus on mRNA therapeutics and extended cash runway are positive, though valuation remains weak due to a negative P/E ratio.

To see Spark’s full report on ARCT stock, click here.

More about Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. operates in the biotechnology industry, focusing on the development of RNA-based therapeutics. The company is known for its innovative approaches in the field of genetic medicine, targeting various diseases with its proprietary technology platforms.

Average Trading Volume: 449,096

Technical Sentiment Signal: Sell

Current Market Cap: $332.5M

For an in-depth examination of ARCT stock, go to TipRanks’ Stock Analysis page.